65,437 trials
Community Acquired Pneumonia (CAP)
Primary: Response Rate (Clinical Response, Data Review Committee Assessment) — 86.3; 84.5; 82.9 percentage of participants
Influenza
Primary: Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) — 0; 0 Participants
Pain, Postoperative
Primary: Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy — 2.5; 5.6 units on a scale
Influenza
Primary: Number of Participants Reporting Solicited Subjective Local Reactions After the First Vaccination — 60; 69; 102; 98 Participants
Herpes Zoster
Primary: Number of Participants With a Negative VZV Skin Test at Baseline (Part A) — 23 Participants
Alcohol Dependence
Primary: Cumulative Percentage of Participants by Heavy Drinking Rate — 40.8; 47.3; 59.2; 59.5 percentage of participants — p=0.336
Age-Related Macular Degeneration · Choroidal Neovascularization
Primary: Monthly Rates of Anti-VEGF (Vascular Endothelial Growth Factor) Injections — 0.42; 0.83; 0.34; 0.83 Injections per Month
Biliary Tract Diseases
Primary: Procedural Success as Defined by: 1. Ability to Visualize Stricture & Obtain Biopsy of Lesion Adequate for Histological Examination in Suspected Malignancy Cases or 2…
Schizophrenia
Primary: Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale)Total Score — -5.0; -5.2; -8.0; -9.8 units on a scale — p=<0.05
Asthma · COPD
Primary: Overall Discrepancy Rate — 0.13 Overall discrepancies per 100 actuations
Influenza, Human
Primary: Number of Participants With Any Adverse Drug Reaction — 4 participants
Childhood Schizophrenia · Psychotic Disorder · Schizophrenia
Primary: Change in the Scale for the Assessment of Negative Symptoms — -14; -25 Scores on a scale — p=.04
Rotavirus Infections
Primary: Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8] — 167.9; 193.2; 171.0; 9.3 dilution units — p=<0.001
Sinusitis, Acute
Primary: Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period (Weeks 1-2) — -2.97; -3.36; -3.33 units on a scale — p=0.008
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in IAUC (Incremental Area Under the Curve) for Postprandial Glucose (0-4 Hours) Over 3 Main Meals — -1.99; -1.977 mmol/L